Healthcare Industry News:  Baroreflex Hypertension Therapy 

Devices FDA

 News Release - October 16, 2006

CVRx(R), Inc., Receives IDE Approval for Rheos(TM) Baroreflex Hypertension Therapy(TM) System Pivotal Trial

MINNEAPOLIS--(HSMN NewsFeed)--CVRx®, Inc., a private medical device company that has developed an implantable medical device to treat high blood pressure, has received a conditional investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a U.S. pivotal clinical trial that will evaluate the safety and effectiveness of the Rheos(TM) Baroreflex Hypertension Therapy(TM) System. Data from this clinical trial is intended to support the Pre-Market Approval (PMA) application for the Rheos System to the FDA.



"The Rheos System represents a fundamentally new approach to therapeutic intervention for resistant hypertension," said the clinical trial's principal investigator, Dr. Thomas Pickering, professor of medicine, Columbia University Medical Center - Presbyterian Hospital. "This pivotal study will help us further understand the potential role of this device in treating patients with difficult-to-manage high blood pressure. Reducing high blood pressure can help prevent serious heart and kidney disease, stroke and death."

Sponsored by CVRx, the blinded study is a prospective, randomized, multi-center clinical trial that will be conducted at up to 40 medical sites in the United States. The study seeks to determine the safety and effectiveness of the Rheos System when used in drug-resistant hypertension patients. To be enrolled in the trial, patients need to be resistant to treatment with at least three anti-hypertension agents, including a diuretic. Their systolic blood pressure must be greater than or equal to 160 mmHg.

"We have seen early positive clinical results with the Rheos System in both Europe and the United States," said Dr. Robert J. Cody, vice president for medical affairs, CVRx. "European results were recently presented at the European Society of Hypertension and the European Society for Vascular Surgery conferences, and initial U.S. results will be presented at the American Heart Association (AHA) annual meeting in November. We are excited to continue the clinical evaluation of the Rheos System in a much larger number of patients and look forward to working with our clinical investigators on this study."

Early Clinical Study Results: European and U.S. feasibility clinical trials are evaluating the Rheos System in hypertension patients. European patients started enrolling in the trial in 2004. Early results for the first 12 patients were reported at the European Society of Hypertension meeting in June 2006. In this study, after three months of active Rheos therapy, systolic blood pressure was reduced by an average of 24 mmHg (189 mmHg vs. 165 mmHg). There were no unanticipated serious adverse events related to the system or procedures. Further information on these study results can be found on the CVRx Web site at www.cvrx.com.

About the Rheos System: CVRx's flagship product, the Rheos Baroreflex Hypertension Therapy System, is intended for use in patients who cannot control their blood pressure with medications and lifestyle modifications. The Rheos System provides what physicians describe as a "physiological rational" method to reduce blood pressure. This implantable device is designed to reduce blood pressure by using mild electrical signals to influence the body's blood pressure regulation system, called the baroreflex.

About High Blood Pressure: High blood pressure, also referred to as hypertension, affects about 65 million people in the United States. Hypertension is a leading cause of stroke, heart attack, heart failure and kidney disease and is estimated to cause one in every eight deaths worldwide. Approximately 25 percent of people with hypertension cannot control their high blood pressure, despite the use of multiple medications.

About CVRx: CVRx, Inc., was founded in 2001 and is headquartered in Minneapolis. It is a private company and its senior management and technical teams have many years of experience commercializing implantable medical devices. For more information visit www.cvrx.com

CAUTION: CVRx Rheos System is an investigational device and is limited by Federal (or United States) law to investigational use only.

CVRx, Rheos, Baroreflex Hypertension Therapy are trademarks of CVRx, Inc. © CVRx, Inc. 2006



Source: CVRx

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.